Climb Bio, INC

Climb Bio, Inc. announced the immediate resignation of director Andrew Levin and the election of Breanna O'Reilly, Ph.D., to its Board of Directors.

Climb Bio, Inc. has entered into a new $100 million at-the-market equity distribution agreement with Jefferies LLC while terminating a previous agreement with Oppenheimer & Co.

Climb Bio announced initial data from its Phase 1b study of budoprutug for primary immune thrombocytopenia (ITP), showing good tolerability and positive platelet responses.

Climb Bio, Inc. held its Annual Meeting of Stockholders on June 5, 2026, where key proposals including amendments to its 2021 Equity Incentive Plan and the election of new directors were approved.

Climb Bio announced favorable initial Phase 1 safety data and translational pharmacometric modeling for its anti-APRIL antibody, CLYM116.

Climb Bio announced first quarter 2026 financial results, highlighting progress in its budoprutug and CLYM116 drug development programs and a $110 million private placement.

Climb Bio, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $13.7 million and a cash balance of $146.3 million, while advancing its key drug candidates.

Climb Bio, Inc. reported a net loss of $12.9 million for Q3 2025, while advancing its lead product candidates budoprutug and CLYM116 in clinical trials.

Climb Bio, a clinical-stage biotech, reported increased operating losses and significant R&D expenses in Q2 2025, driven by pipeline advancements, while maintaining a cash runway through 2027.

Climb Bio, a clinical-stage biotechnology company, announces its financial results for the first quarter of 2025, highlighting progress in its clinical development programs for immune-mediated diseases.

Climb Bio, formerly Eliem Therapeutics, reports its third quarter 2024 results, highlighting a strategic shift to immune-mediated diseases and progress in the development of its lead candidate, budoprutug.

Eliem Therapeutics reports a net loss of $54.9 million for the second quarter of 2024, which includes a significant expense related to the acquisition of Tenet Medicines.

Climb Bio, Inc. reported a net loss of $59.9 million for fiscal year 2025, while actively progressing its lead product candidates, budoprutug and CLYM116, through multiple clinical trials for immune-mediated diseases.

Climb Bio, a clinical-stage biotechnology company, reports its full year 2024 results and highlights progress in its pipeline of therapies targeting immune-mediated diseases, including budoprutug and CLYM116.

Eliem Therapeutics has filed an amendment to its annual report on Form 10-K, primarily to include information required by Part III regarding directors, executive compensation, and corporate governance.

Eliem Therapeutics outlines a transition, separation, and consulting agreement for an executive, including enhanced severance benefits and a consulting engagement.

RA Capital Management, L.P. and its affiliated funds have reported changes in beneficial ownership related to Climb Bio, Inc. (CLYM), including the acquisition of stock options.

Climb Bio, Inc. director Breanna Maurine Celebi reported the acquisition of a stock option for 70,284 shares.

Climb Bio, Inc. President and CEO Aoife Brennan reports significant stock transactions, including RSU vesting and a sale under a 10b5-1 plan.

RA Capital Management disclosed a stock option grant for 40,000 shares awarded to Dr. Andrew Levin for his service on the Climb Bio board.

Director Andrew David Levin was granted 40,000 stock options in Climb Bio, Inc. to be held for the benefit of RA Capital Management.

Director Kimberlee C. Drapkin was granted 40,000 stock options in Climb Bio, Inc. as part of a standard equity compensation arrangement.

Climb Bio, Inc. has issued its 2026 proxy statement detailing director elections, auditor ratification, and proposed amendments to its certificate of incorporation and equity incentive plan.

Climb Bio, Inc. has announced the mutual separation of its Chief Operating Officer and principal financial officer, Brett Kaplan, M.D., effective May 23, 2025, and the immediate appointment of Aoife Brennan as interim principal financial officer.

Climb Bio, Inc. will hold its annual meeting of stockholders virtually on June 4, 2025, to elect two directors and ratify the selection of PricewaterhouseCoopers LLP as its independent auditor.

Climb Bio, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 4, 2025, to elect directors and ratify the selection of its independent registered public accounting firm.

Eliem Therapeutics issues a supplement to its definitive proxy statement to address stockholder lawsuits and provide additional information regarding the acquisition of Tenet Medicines, Inc.

Eliem Therapeutics has supplemented its definitive proxy statement regarding the upcoming annual meeting, highlighting the appointment of Aoife Brennan as CEO and Stephen Thomas as a director, contingent on the closing of the Tenet Medicines acquisition.

RA Capital Management, L.P. and its affiliates have updated their Schedule 13D filing, reporting a beneficial ownership of 33.0% in Climb Bio, Inc. following a board appointment and stock distribution.

RA Capital Management disclosed a significant investment in Climb Bio, Inc. through a private placement of common stock and pre-funded warrants.

RA Capital Management and affiliated funds have amended their Schedule 13D filing for Climb Bio, Inc., converting a significant portion of common stock into pre-funded warrants and detailing recent open market purchases.

Access Industries and its affiliates have fully divested their beneficial ownership in Climb Bio, Inc., selling over 3.8 million shares in recent block trades.

Access Industries entities and Len Blavatnik have reduced their beneficial ownership in Climb Bio, Inc. to 5.66% through recent share sales.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 11.9% in Climb Bio Inc. as of June 30, 2026.

Investment funds managed by Pontifax have reported a 7.7% beneficial ownership stake in Climb Bio, Inc. common stock.

BML Investment Partners, L.P. and Leonard Braden Michael have reported a complete divestment of their beneficial ownership in Climb Bio, Inc., reducing their stake to 0% of the common stock.